1.01BMarket Cap-14.00P/E (TTM)
10.670High10.300Low324.65KVolume10.510Open10.535Pre Close3.37MTurnover0.38%Turnover RatioLossP/E (Static)96.36MShares19.09052wk High13.55P/B890.22MFloat Cap9.41052wk Low--Dividend TTM84.78MShs Float43.600Historical High--Div YieldTTM3.51%Amplitude0.710Historical Low10.376Avg Price1Lot Size
Avadel Pharmaceuticals Stock Forum
yeah, cluster buys drew my attention too
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challen...
🎃⚡️🎃
Given its current financial standing and market movements, Avadel Pharmaceuticals is assessed as a moderately high-risk investment. The company's unprofitability, negative cash flow, and strong dependency on news-related catalysts pose potential risks. Nonetheless, the recently improved stock sentiment, coupled with analysts' positive forecasts, suggests some upside potential. The relatively high position in its volatility scale underscores the need for caution,...
📊⚡️📊
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
No comment yet